Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Clin Cancer Res. 2017 Sep 12;23(22):7072–7083. doi: 10.1158/1078-0432.CCR-17-0413

Figure 4. Metastatic tumors with concurrent TOP2A and EZH2 expression maintain a set of differentially expressed genes that overlap with TOP2A+/EZH2+ primary PCa.

Figure 4

(A) Unsupervised clustering analysis of metastatic PCa data demonstrates that patients with concurrent high TOP2A and EZH2 expression (TOP2A+/EZH2+; green) tightly cluster apart from other patients (purple) based on their differentially expressed genes (DEGs). (B) Unique DEGs between TOP2A+/EZH2+ and other patients was validated by PCA. (C) An important proportion of DEGs in TOP2A+/EZH2+ metastatic prostate cancer patients are shared between Robinson et al. (2015) and Kumar et al. (2016) datasets. (D) GSEA revealed statistically significant enrichment of gene signatures involved mitosis and E2F signaling, P < 0.05 and FDR < 0.15. (E, F) Comparison of gene expression platforms including (E) RNA-seq and (F) microarray revealed that shared gene expression was maintained between TOP2A+/EZH2+ primary and metastatic PCa patients.